ArticleJournal of Alzheimer's disease reports
Association between Gompertz law-based biological age (GOLD BioAge) and incident mild cognitive impairment: Modifying role of social activeness.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mild cognitive impairment (MCI) is an important transitional stage between normal cognitive aging and dementia. Biomarker-based biological age may better capture physiological aging processes than chronological age, yet its association with the risk of developing MCI remains insufficiently studied. Objective: We aimed to examine the association between Gompertz Law-Based Biological Age (Light BioAge) and incident MCI in a middle-aged and older Chinese population, and to explore whether social activeness modifies this association. Methods: We used data from the China Health and Retirement Longitudinal Study, a nationally representative cohort. Light BioAge was calculated from chronological age, serum creatinine, fasting glucose, and C-reactive protein. Incident MCI was defined using age- and education-standardized cognitive assessments. Cox regressions were used to analysis. Results: Among 9410 participants free of MCI at baseline, 1047 developed MCI during follow-up. Light BioAge was negatively associated with risk of MCI (hazards ratio (HR) = 0.99, 95% CI: 0.98-0.99). Compared to high Light BioAge, those in the moderate and low groups showed significantly lower risks of MCI (HR = 0.78, 95% CI: 0.65-0.94 and HR = 0.79, 95% CI: 0.65-0.97, respectively). The association were consistent across sex and different levels of social activeness, with no significant interaction observed. Conclusions: Lower biological age, as estimated by Light BioAge, is independently associated with a reduced risk of MCI in middle-aged and older adults. The use of biomarker-based aging indicators may help identify individuals at higher risk of cognitive decline for early preventive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.